- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Longeveron files $70M mixed securities shelf | 1 | Seeking Alpha | ||
| 20.03. | Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease | 207 | GlobeNewswire (Europe) | Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseAlignment with FDA on proposed trial study design... ► Artikel lesen | |
| 14.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's Disease | 183 | GlobeNewswire (Europe) | Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data... ► Artikel lesen | |
| 03.03. | Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 28.02. | Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update | 303 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more... ► Artikel lesen | |
| 28.02. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 28.02. | Longeveron Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 18.02. | Longeveron Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B | 1 | GlobeNewswire (USA) | ||
| 30.01. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.12.24 | Longeveron to Present at Biotech Showcase 2025 | 3 | GlobeNewswire (USA) | ||
| 13.11.24 | Longeveron reports Q3 results | 3 | Seeking Alpha | ||
| 12.11.24 | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.11.24 | A Look Ahead: Longeveron's Earnings Forecast | 5 | Benzinga.com | ||
| 11.11.24 | Longeveron ernennt Devin Blass zum neuen CTO | 2 | Investing.com Deutsch | ||
| 11.11.24 | Longeveron names Devin Blass as new CTO | 1 | Investing.com | ||
| 11.11.24 | Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) | 2 | GlobeNewswire (USA) | ||
| 04.11.24 | Peeling Back The Layers: Exploring Longeveron Through Analyst Insights | 1 | Benzinga.com | ||
| 27.10.24 | Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting | 132 | GlobeNewswire (Europe) | Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none... ► Artikel lesen | |
| 10.07.24 | Pre-market Movers: VivoPower, NaaS Technology, Ampco-Pittsburgh, LegalZoom.com, Longeveron | 770 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green VivoPower International PLC (VVPR) is up over 90%... ► Artikel lesen |
Seite:
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,55 | -1,67 % | BioNTech-Aktie: Das muss man wirklich wissen! | News von Trading-Treff.de BioNTech hat sich sehr stark in die neue Woche eingeklinkt. Das Unternehmen konnte ein Plus in Höhe von 2,6 % verzeichnen. Schon am Freitag war es an der US-Börse NASDAQ um... ► Artikel lesen | |
| CUREVAC | 2,766 | +0,36 % | CureVac, Evotec, Knaus Tabbert, Laiqon, NVIDIA, ThyssenKrupp - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 33,200 | +0,30 % | Goldman Sachs maintains Neutral on CRISPR Therapeutics stock | ||
| OCUGEN | 0,593 | -1,36 % | Ocugen Aktie: Attraktive Möglichkeiten entdeckt! | Trotz Jahresrückgangs zeigt das US-Biotechnologieunternehmen eine beeindruckende 7-Tage-Performance mit positiven Analystenprognosen bei der Gentherapie-Entwicklung. Die Aktie des US-Biotechnologieunternehmens... ► Artikel lesen | |
| CYTODYN | 0,168 | 0,00 % | CytoDyn Inc. - 10-Q, Quarterly Report | ||
| SOL GLOBAL INVESTMENTS | 0,054 | +3,88 % | SOL Global Investments Corp.: SOL Global Announces Update on C$10 Million Debenture Private Placement from Strategic Investor | Toronto, Ontario--(Newsfile Corp. - March 21, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional... ► Artikel lesen | |
| CELLECTIS | 1,332 | -1,04 % | Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update | ? UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 7,772 | -1,30 % | Anavex Life Sciences Aktie: Positive Überraschung im Halbjahr | Biotech-Aktie mit starkem Jahresplus verzeichnet leichten Rückgang. Phase-III-Studien und hohe Kursziele wecken Interesse. Wird der Quartalsbericht im Mai neue Impulse setzen? Die Anavex Life Sciences-Aktie... ► Artikel lesen | |
| CERUS | 1,131 | -0,70 % | Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update | CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product revenue guidance for... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 1,150 | +0,88 % | Windtree Therapeutics zeigt beeindruckende finanzielle Erholung | ||
| APTEVO THERAPEUTICS | 0,928 | -6,64 % | Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules | SEATTLE, WASHINGTON / ACCESS Newswire / April 4, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology... ► Artikel lesen | |
| TRACON PHARMACEUTICALS | 1,410 | 0,00 % | Tracon Pharmaceuticals, Inc. - 15-12G, Securities registration termination | ||
| HARVARD BIOSCIENCE | 0,354 | +3,51 % | Benchmark reiterates Harvard Bioscience stock with $4.50 target | ||
| ENTERA BIO | 1,518 | -0,13 % | Entera Bio reports positive phase 2 results for osteoporosis treatment | ||
| XBRANE BIOPHARMA | 0,013 | +2,33 % | Xbrane Biopharma AB: Announcement from extra general meeting in Xbrane Biopharma AB | Today on 14 April 2025 the extra general meeting of Xbrane Biopharma AB (the "Company") was held and the following resolutions were passed by the meeting. Resolution regarding approval of sale of certain... ► Artikel lesen |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,415 Euro und damit -3,74 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.
